175 related articles for article (PubMed ID: 11239186)
1. Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke.
Lees KR; Sharma AK; Barer D; Ford GA; Kostulas V; Cheng YF; Odergren T
Stroke; 2001 Mar; 32(3):675-80. PubMed ID: 11239186
[TBL] [Abstract][Full Text] [Related]
2. Tolerability of NXY-059 at higher target concentrations in patients with acute stroke.
Lees KR; Barer D; Ford GA; Hacke W; Kostulas V; Sharma AK; Odergren T;
Stroke; 2003 Feb; 34(2):482-7. PubMed ID: 12574564
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetic modelling and estimation of dosing strategy for NXY-059, a nitrone being developed for stroke.
Jönsson S; Cheng YF; Edenius C; Lees KR; Odergren T; Karlsson MO
Clin Pharmacokinet; 2005; 44(8):863-78. PubMed ID: 16029070
[TBL] [Abstract][Full Text] [Related]
4. NXY-059 for acute ischemic stroke.
Lees KR; Zivin JA; Ashwood T; Davalos A; Davis SM; Diener HC; Grotta J; Lyden P; Shuaib A; Hårdemark HG; Wasiewski WW;
N Engl J Med; 2006 Feb; 354(6):588-600. PubMed ID: 16467546
[TBL] [Abstract][Full Text] [Related]
5. NXY-059: review of neuroprotective potential for acute stroke.
Fong JJ; Rhoney DH
Ann Pharmacother; 2006 Mar; 40(3):461-71. PubMed ID: 16507608
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability and pharmacokinetics of escalating doses of NXY-059 in healthy young and elderly subjects.
Wemer J; Cheng YF; Nilsson D; Reinholdsson I; Fransson B; Lanbeck Vallén K; Nyman L; Eriksson C; Björck S; Schulman S
Curr Med Res Opin; 2006 Sep; 22(9):1813-23. PubMed ID: 16968585
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of 8-hour intravenous infusion of NXY-059: a phase I, randomized, double-blind (within dose panels), placebo-controlled study in healthy Chinese volunteers.
Cheng YF; Jiang J; Hu P; Reinholdsson I; Guo W; Asenblad N; Nilsson D
Clin Ther; 2008 Dec; 30(12):2342-53. PubMed ID: 19167593
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke.
Strid S; Borgå O; Edenius C; Jostell KG; Odergren T; Weil A
Eur J Clin Pharmacol; 2002 Sep; 58(6):409-15. PubMed ID: 12242600
[TBL] [Abstract][Full Text] [Related]
9. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials.
Diener HC; Lees KR; Lyden P; Grotta J; Davalos A; Davis SM; Shuaib A; Ashwood T; Wasiewski W; Alderfer V; Hårdemark HG; Rodichok L;
Stroke; 2008 Jun; 39(6):1751-8. PubMed ID: 18369171
[TBL] [Abstract][Full Text] [Related]
10. A phase 1, placebo-controlled, randomised, double-blind (within dose panels) study evaluating the safety, tolerability and pharmacokinetics of intravenous NXY-059 in Japanese subjects.
Watabe M; Cheng YF; Nilsson D; Itoh Y; Kumagai Y
Curr Med Res Opin; 2007 Aug; 23(8):1849-57. PubMed ID: 17605894
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of NXY-059 for acute intracerebral hemorrhage: the CHANT Trial.
Lyden PD; Shuaib A; Lees KR; Davalos A; Davis SM; Diener HC; Grotta JC; Ashwood TJ; Hardemark HG; Svensson HH; Rodichok L; Wasiewski WW; Ahlberg G;
Stroke; 2007 Aug; 38(8):2262-9. PubMed ID: 17569876
[TBL] [Abstract][Full Text] [Related]
12. Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion.
Marshall JW; Cummings RM; Bowes LJ; Ridley RM; Green AR
Stroke; 2003 Sep; 34(9):2228-33. PubMed ID: 12920263
[TBL] [Abstract][Full Text] [Related]
13. NXY 059: CPI 22, NXY 059G.
Adis International Ltd
Drugs R D; 2003; 4(4):254-7. PubMed ID: 12848592
[TBL] [Abstract][Full Text] [Related]
14. NXY-059, a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat.
Zhao Z; Cheng M; Maples KR; Ma JY; Buchan AM
Brain Res; 2001 Aug; 909(1-2):46-50. PubMed ID: 11478919
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of disodium 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (NXY-059), a free radical trapping agent, in a rat model of hemorrhagic stroke.
Peeling J; Del Bigio MR; Corbett D; Green AR; Jackson DM
Neuropharmacology; 2001 Mar; 40(3):433-9. PubMed ID: 11166336
[TBL] [Abstract][Full Text] [Related]
16. NXY-059, a free radical--trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species.
Marshall JW; Duffin KJ; Green AR; Ridley RM
Stroke; 2001 Jan; 32(1):190-8. PubMed ID: 11136936
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat.
Kuroda S; Tsuchidate R; Smith ML; Maples KR; Siesjö BK
J Cereb Blood Flow Metab; 1999 Jul; 19(7):778-87. PubMed ID: 10413033
[TBL] [Abstract][Full Text] [Related]
18. Nitrone-related therapeutics: potential of NXY-059 for the treatment of acute ischaemic stroke.
Maples KR; Green AR; Floyd RA
CNS Drugs; 2004; 18(15):1071-84. PubMed ID: 15581379
[TBL] [Abstract][Full Text] [Related]
19. Effects of the spin trap agent disodium- [tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit Large clot embolic stroke model: combination studies with tissue plasminogen activator.
Lapchak PA; Araujo DM; Song D; Wei J; Purdy R; Zivin JA
Stroke; 2002 Jun; 33(6):1665-70. PubMed ID: 12053009
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator.
Lapchak PA; Araujo DM; Song D; Wei J; Zivin JA
Stroke; 2002 May; 33(5):1411-5. PubMed ID: 11988623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
